The analysis of tumor cells or tumor cell products obtained from blood or other body fluids
(“liquid biopsy”[LB]) provides a broad range of opportunities in the field of oncology. Clinical …

Cancer biomarkers have transformed current practices in the oncology clinic. Continued
discovery and validation are crucial for improving early diagnosis, risk stratification, and …

Urine is commonly used for clinical diagnosis and biomedical research. The discovery of
extracellular vesicles (EV) in urine opened a new fast‐growing scientific field. In the last …

Background Global development goals increasingly rely on country-specific estimates for
benchmarking a nation's progress. To meet this need, the Global Burden of Diseases …

Prostate cancer is a global cancer burden and considerable effort has been made through
the years to identify biomarkers for the disease. Approximately a decade ago, the potential of …

Prostate cancer (PCa) is a leading cause of cancer death for males in western countries.
The current gold standard for PCa diagnosis-template needle biopsies-often does not …

Cancer cells release small extracellular vesicles, exosomes, that have been shown to
contribute to various aspects of cancer development and progression. Differential analysis of …

Extensive medical research showed that patients, with high protein concentration in urine,
have various kinds of kidney diseases, referred to as proteinuria. Urinary protein biomarkers …

Mounting evidence indicates that tumor-derived exosomes (TDEs) play critical roles in tumor
development and progression by regulating components in the tumor microenvironment …

The development of more specific biomarkers for prostate cancer and/or high‐risk prostate
cancer is necessary, because the prostate‐specific antigen test lacks specificity for the …